Potential repositioning of GV1001 as a therapeutic agent for testosterone-induced benign prostatic hyperplasia
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE42(4) · pp.2260 · 2018
- 피인용
- Web of Science 13Scopus 15
- FWCI (Scopus)
- 0.25
- JCR IF
- JCR 2017 2.784
- ISSN
- 1107-3756
저자
- Kim, Kyeong Seok제1저자Department of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea
- Yang, Hun YongDepartment of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea
- 장승철Institute of Bio-Physio Sensor Technology, Center for Proteome Biophysics, Pusan National University, Busan, South Korea
- Kim, Young-MiCollege of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, South Korea
- Lee, Kwang YoulCollege of Pharmacy, Research Institute of Drug Development, Chonnam National University, Gwangju, Gwangju, South Korea
- Lee, Byung MuDepartment of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea
- Kim, Hyung Sik교신저자Department of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea
초록
Benign prostatic hyperplasia (BPH) is one of the leading causes of male reproductive disorders. Therapeutic agents currently in use have severe side effects; therefore, alternative drugs that exhibit improved therapeutic activity without side effects are required. The present study investigated the protective effect of GV1001 against testosterone-induced BPH in rats. BPH in castrated rats was established via daily subcutaneous (s.c.) injections of testosterone propionate (TP, 3 mg/kg) dissolved in corn oil for 4 weeks. GV1001 (0.01, 0.1 and 1 mg/kg, s.c.) was administered 3 times per week for 4 weeks, together with TP (3 mg/kg) injection. The rats were sacrificed on the last day of treatment, and their prostates were excised and weighed for biochemical and histological studies. Serum levels of testosterone and dihydrotestosterone (DHT) were also measured. In rats with TP-induced BPH, a significant increase in prostate weight (PW) and prostatic index (PI), accompanied by a decrease in antioxidant enzyme activity, was observed. Histological studies revealed clearly enlarged glandular cavities in rats with BPH. GV1001 (0.01 and 0.1 mg/kg) treatment significantly decreased PW and PI in rats with TP-induced BPH. In addition, GV1001 demonstrated a potent inhibitory effect on 5 alpha-reductase in prostate. The present data suggest that the protective role of GV1001 against testosterone-induced BPH is closely associated with its antioxidant potential. Additional studies are required to identify the mechanisms by which GV1001 protects against BPH to determine its clinical application.
키워드
GV1001benign prostate hyperplasiaantioxidants5 alpha-reductaseTELOMERASE PEPTIDE VACCINATIONOXIDATIVE STRESSANTIOXIDANT STATUSPHASE-I/IICANCERINFLAMMATIONEXTRACTGROWTHINJURYRATS
식별자
- Scopus EID
- 2-s2.0-85052397220
- WoS UID
- 000442971000050



로그인
연구물 목록으로